Xiaojiao Li

机构：Jilin University, First Hospital of Jilin University · ORCID：0000-0001-5999-0035

发表论文 96 篇 · 总被引 1302 次 · h-index 20

代表论文

• Role of leptin and adiponectin in immune response and inflammation (2025 · International Immunopharmacology · 被引 43)
• Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study (2024 · Journal of Hepatology · 被引 38)
• Development of a CT radiomics nomogram for preoperative prediction of Ki-67 index in pancreatic ductal adenocarcinoma: a two-center retrospective study (2023 · European Radiology · 被引 24)
• Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial (2023 · BMC Medicine · 被引 21)
• Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials (2024 · The Lancet Infectious Diseases · 被引 20)
• Sex Differences of the Functional Brain Activity in Treatment-Resistant Depression: A Resting-State Functional Magnetic Resonance Study (2022 · Brain Sciences · 被引 19)